Table 3.
Overall potential for clot formation and lysis kinetic parameters (mean ± SD) of the control group and patients with metabolic syndrome at baseline and after 1 and 2 months of A. melanocarpa extract therapy
| Phase | Parameter | Patients with metabolic syndrome | Control group | ||
|---|---|---|---|---|---|
| Baseline | 1 month | 2 months | |||
| I | Tt (s) | 34.8 ± 5.7 | 39.81 ± 19.8 | 38.0 ± 8.9 | 35.6 ± 3.5 |
| Fmax (%T) | 46.9 ± 8.7 | 40.0 ± 12.1+++ | 43.2 ± 11.3 | 47.7 ± 13.0 | |
| Tf (s) | 103.1 ± 27.2* | 94.0 ± 22.0++ | 97.1 ± 28.4 | 90.5 ± 25.9 | |
| Fvo (%T/min) | 68.0 ± 24.1** | 69.8 ± 32.7** | 72.8 ± 29.5* | 99.2 ± 40.7 | |
| Sf (%T × min) | 55.0 ± 19.8 | 42.7 ± 14.8++ | 48.5 ± 22.7 | 50.9 ± 17.0 | |
| II | Tc (s) | 431.7 ± 82.4** | 426.9 ± 125.0** | 443.7 ± 86.9** | 364.0 ± 66.7 |
| Sc (%T × min) | 329.9 ± 93.7 | 289.0 ± 115.6++ | 307.2 ± 95.7 | 278.8 ± 79.6 | |
| III | Lmax (%T) | 43.4 ± 11.2 | 38.14 ± 14.0++ | 41.9 ± 11.7 | 44.5 ± 10.9 |
| Tl (s) | 268.2 ± 61.4 | 283.7 ± 62.6++ | 289 ± 54.4 | 241.9 ± 57.7 | |
| Lvo (%T/min) | 14.5 ± 6.5 | 12.0 ± 6.4 | 13.8 ± 7.3 | 19.3 ± 16.2 | |
| Sl (%T × min) | 135.4 ± 54.5 | 110.1 ± 48.4+++ | 114.4 ± 36.1 | 116.6 ± 35.8 | |
| CLAUC (%T × min) | 518.6 ± 155.2* | 442.1 ± 170.7++ | 470.6 ± 146.5 | 446.3 ± 123.4 | |
| Fb (mg/dL) | 290.9 ± 78.2*** | 281.9 ± 70.9** | 322.5 ± 68.0+++/** | 214.7 ± 36.7 | |
Phase I (clot formation): Tt thrombin time, F max maximum clotting, Tf plasma clotting time, Fvo initial plasma clotting velocity, S r area under the clot formation curve; Phase II (forming a stable): Tc clot stabilization time, S c area under the curve of a stable clot formation; Phase III (fibrinolysis): L max maximum lysis, Tl fibrinolysis time, Lvo initial clot fibrinolysis velocity, S f area under the fibrinolysis curve; CL AUC overall potential for clot formation and lysis, Fb fibrinogen
*** p < 0.001; ** p < 0.05; * p = 0.05 versus control group; + p = 0.05; ++ p < 0.05 versus baseline